Elizabeth Xiao-Ru Wang is an Executive Vice President with Compass Lexecon and specializes in antitrust issues in regulatory and litigation settings. She has provided economic analyses on issues of merger review, commercial disputes and antitrust investigation, especially in cross-border matters. She has been involved in casework in a variety of industries, including healthcare, high tech, financial markets, pharmaceuticals, airlines, intellectual property rights and consumer products. Dr. Wang has submitted reports to government antitrust agencies in the United States and in China, and has testified in both Chinese courts and an US congressional hearing. She has published and spoken frequently on antitrust and IP issues, and has been named to the International Who’s Who Legal: Competition Economists list numerous times.

Dr. Wang has extensive experience working on antitrust matters with Asian regulators. She has advised clients on merger reviews, antitrust investigations and private litigation in APAC countries. Dr. Wang has worked with clients in Asia, North America and Europe. She is highly knowledgeable about cultural and legal system differences across countries, and works with clients to navigate challenges associated with regulatory reviews and dispute resolutions.

Dr. Wang has a Ph.D. in Economics from the University of Chicago in the United States and a B.A. in Economics from Peking University in China. She is a native Chinese speaker and is fluent in English.

Dr. Wang is active in the American Bar Association (ABA). She is a Co-Chair of the International Antitrust Committee at the ABA Section of International Law and won the ABA International Law Section Award of Outstanding Collaboration between Committees in 2014. Dr. Wang is also an active member at the ABA Section of Antitrust Law.